SVRA
$5.15
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3...
Recent News
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed
Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, granting Priority Review with a PDUFA action date of August 22, 2026. This filing adds to MOLBREEVI’s existing Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations, underscoring its potential importance for a rare respiratory disease with limited treatment...
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears
Savara (NASDAQ:SVRA) executives highlighted recent regulatory and commercial milestones for its lead program, molgramostim inhalation solution (Molbreevi), during a discussion at Oppenheimer’s 36th Annual Healthcare Life Science Conference. Management said the U.S. Food and Drug Administration (FDA)
Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit
Savara (NASDAQ:SVRA) executives provided an update on the company’s regulatory timeline, manufacturing changes, clinical evidence, and commercial preparations for MOLBREEVI during a presentation at Guggenheim’s Emerging Outlook Biotech Summit. Company focus and near-term regulatory timeline Chair a
High Growth Tech Stocks To Watch In The US Market
As the U.S. stock market kicked off February with significant gains, highlighted by the Dow Jones Industrial Average's 515-point surge and the S&P 500 nearing a record high, investors are keenly observing how these developments impact high-growth tech stocks. In such a dynamic environment, identifying promising tech stocks often involves looking at companies that demonstrate strong innovation potential and adaptability to market shifts.